• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>CV Therapeutics

CV Therapeutics

  1. Emerging Markets Mid-Year Pulse Check

    CV Therapeutics CVTX announced on Monday that it plans to sell 7.5 million shares in an offering. This will increase the firm's shares by roughly 15%, and we'll lower our fair value estimate by a similar magnitude once the offering is completed. We're a little surprised to see the firm issue equity ...

  2. How Best to See a Stock’s Value

    Given recent trial results and CV Therapeutics' CVTX financial position, we are placing the company under review to re-evaluate our assumptions about its capital-raising opportunities and Ranexa's peak sales if it receives approval as a first-line therapy for chronic angina.

  3. Morningstar's 2014 CEO of the Year

    Gilead's John Martin has established leading market share and spectacular profitability for the innovative biotech firm.

©2017 Morningstar Advisor. All right reserved.